-
1.发明授权Method of treating skin wounds with vectors encoding hepatocyte growth factor 有权用编码肝细胞生长因子的载体处理皮肤伤口的方法公开(公告)号：US07247620B2
公开(公告)日：2007-07-24
申请号：US10477166
申请日：2002-05-09
CPC分类号： A61K38/1709 , A61K38/1825 , A61K38/1833 , A61K38/1866 , A61K48/005
摘要： The present invention relates to a therapeutic preventive agent that includes an angiogenic factor gene (such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and hypoxia inducible factor (HIF)) as its active ingredient, and the administration of such an agent into the targeted skin diseases-affected area.
摘要翻译： 本发明涉及包含血管生成因子基因（如肝细胞生长因子（HGF），血管内皮生长因子（VEGF）），成纤维细胞生长因子（FGF）和缺氧诱导因子（HIF））的治疗性预防药物 活性成分，以及将这种药剂施用于目标皮肤疾病影响区域。
-
2.发明授权Method of treating skin ulcers with vectors encoding hepatocyte growth factor 有权用编码肝细胞生长因子的载体治疗皮肤溃疡的方法公开(公告)号：US07939504B2
公开(公告)日：2011-05-10
申请号：US11763361
申请日：2007-06-14
CPC分类号： A61K38/1709 , A61K38/1825 , A61K38/1833 , A61K38/1866 , A61K48/005
摘要： The present invention relates to a therapeutic preventive agent that includes an angiogenic factor gene (such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), fibroblast growth f actor (FGF), and hypoxia inducible factor (HIF)) as its active ingredient, and the administration of such an agent into the targeted skin diseases-affected area.
摘要翻译： 本发明涉及包含血管生成因子基因（例如肝细胞生长因子（HGF），血管内皮生长因子（VEGF），成纤维细胞生长因子（FGF）和缺氧诱导因子（HIF））的治疗性预防药物 其活性成分，以及将这种药物施用于目标皮肤疾病影响区域。
-
3.发明申请METHOD OF TREATING SKIN WOUNDS WITH VECTORS ENCODING HEPATOCYTE GROWTH FACTOR 有权用编码肝细胞生长因子的向量处理皮肤伤口的方法公开(公告)号：US20070264321A1
公开(公告)日：2007-11-15
申请号：US11763361
申请日：2007-06-14
IPC分类号： A61K31/711 , A61K9/127 , A61P17/02 , C12N15/63
CPC分类号： A61K38/1709 , A61K38/1825 , A61K38/1833 , A61K38/1866 , A61K48/005
摘要： The present invention relates to a therapeutic preventive agent that includes an angiogenic factor gene (such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), fibroblast growth f actor (FGF), and hypoxia inducible factor (HIF)) as its active ingredient, and the administration of such an agent into the targeted skin diseases-affected area.
摘要翻译： 本发明涉及包含血管生成因子基因（例如肝细胞生长因子（HGF），血管内皮生长因子（VEGF），成纤维细胞生长因子（FGF）和缺氧诱导因子（HIF））的治疗性预防药物 其活性成分，以及将这种药物施用于目标皮肤疾病影响区域。
-
公开(公告)号：US09012417B2
公开(公告)日：2015-04-21
申请号：US10468717
申请日：2002-02-06
IPC分类号： A61K48/00 , A61K31/711 , A61K38/17 , C12N15/113
CPC分类号： A61K31/711 , A61K38/1709 , C12N15/113 , C12N2310/13
摘要： A pharmaceutical composition for performing treatment against a skin disease, the pharmaceutical composition comprising at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy may be selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The at least one decoy may be an oligonucleotide including at least two decoys bonded to each other, the at least two decoys being selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The skin disease may be atopic dermatitis, psoriasis vulgaris, contact dermatitis, keloid, bedsore, ulcerative colitis, or Crohn's disease.
摘要翻译： 一种用于对皮肤病进行治疗的药物组合物，所述药物组合物包含至少一种诱饵和药学上可接受的载体。 所述至少一个诱饵可以选自NF-和kgr B诱饵，STAT-1诱饵，GATA-3诱饵，STAT-6诱饵，AP-1诱饵和Ets诱饵。 所述至少一个诱饵可以是包含至少两个彼此键合的诱饵的寡核苷酸，所述至少两个诱饵选自由NF-和κB诱饵，STAT-1诱饵，GATA-3诱饵 ，STAT-6诱饵，AP-1诱饵和Ets诱饵。 皮肤病可能是特应性皮炎，寻常型牛皮癣，接触性皮炎，瘢痕疙瘩，褥疮，溃疡性结肠炎或克罗恩病。
-
5.发明申请公开(公告)号：US20090105183A1
公开(公告)日：2009-04-23
申请号：US12314009
申请日：2008-12-02
IPC分类号： A61K31/7088 , A61P17/00
CPC分类号： A61K31/711 , A61K38/1709 , C12N15/113 , C12N2310/13
摘要： A pharmaceutical composition for performing treatment against a skin disease, the pharmaceutical composition comprising at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy may be selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The at least one decoy may be an oligonucleotide including at least two decoys bonded to each other, the at least two decoys being selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The skin disease may be atopic dermatitis, psoriasis vulgaris, contact dermatitis, keloid, bedsore, ulcerative colitis, or Crohn's disease.
摘要翻译： 一种用于对皮肤病进行治疗的药物组合物，所述药物组合物包含至少一种诱饵和药学上可接受的载体。 所述至少一个诱饵可以选自NF-κB诱饵，STAT-1诱饵，GATA-3诱饵，STAT-6诱饵，AP-1诱饵和Ets诱饵。 所述至少一个诱饵可以是包含至少两个彼此键合的诱饵的寡核苷酸，所述至少两个诱饵选自NF-κB诱饵，STAT-1诱饵，GATA-3诱饵， STAT-6诱饵，AP-1诱饵和Ets诱饵。 皮肤病可能是特应性皮炎，寻常型牛皮癣，接触性皮炎，瘢痕疙瘩，褥疮，溃疡性结肠炎或克罗恩病。
-
公开(公告)号：US20090082263A1
公开(公告)日：2009-03-26
申请号：US11658897
申请日：2005-07-29
IPC分类号： A61K38/18 , A61K31/7088 , C07K14/475
CPC分类号： A61K38/1858 , A01K67/027 , A61K38/1825 , A61K38/1833 , A61K48/00
摘要： It is intended to provide a novel remedy for improving the brain function or preventing the same from worsening and a novel administration method for the remedy. Namely, a composition for preventing the brain function from worsening or improving the brain function which contains a cell growth factor. It is preferred that this cell growth factor is one selected from the group consisting of vascular endothelial growth factors (VEGFs), fibroblast growth factors (FGFs) and hepatocyte growth factors (HGFs). A method for preventing the brain function from worsening or improving the brain function which comprises the step of administering a cell growth factor to a patient.
摘要翻译： 旨在提供改善脑功能或防止其相同恶化的新颖的治疗方法以及用于治疗的新型治疗方法。 即，用于防止脑功能恶化或改善包含细胞生长因子的脑功能的组合物。 优选该细胞生长因子是选自血管内皮生长因子（VEGF），成纤维细胞生长因子（FGF）和肝细胞生长因子（HGF））中的一种。 一种防止脑功能恶化或改善脑功能的方法，包括向患者施用细胞生长因子的步骤。
-
公开(公告)号：US07390482B2
公开(公告)日：2008-06-24
申请号：US10527195
申请日：2003-10-02
申请人： Yasufumi Kaneda , Kazuo Oshima , Ryuichi Morishita , Takeshi Kubo
发明人： Yasufumi Kaneda , Kazuo Oshima , Ryuichi Morishita , Takeshi Kubo
CPC分类号： C07K14/4753 , A61K38/1833 , A61K48/00 , A61K48/005 , C12N2799/021
摘要： The present invention provides a pharmaceutical preparation for hearing impairment, which is suitable for gene therapy of hearing impairment, that is, a pharmaceutical preparation for hearing impairment which comprises a virus envelope vector encapsulating a hepatocyte growth factor (HGF) gene or its plasmid as an active ingredient. Particularly, it is suitable as a pharmaceutical preparation for gene therapy for the purpose of prevention and treatment of deafness.
摘要翻译： 本发明提供一种适用于听力障碍的基因疗法的听力损伤药物制剂，即用于听觉障碍的药物制剂，其包含包封肝细胞生长因子（HGF）基因的病毒包膜载体或其质粒作为 有效成分。 特别地，作为用于预防和治疗耳聋的基因治疗的药物制剂是合适的。
-
公开(公告)号：US07259149B2
公开(公告)日：2007-08-21
申请号：US10536274
申请日：2003-12-02
CPC分类号： C07K14/475 , A61K48/0016 , A61K48/0083 , C07K14/4753 , C12N9/0073
摘要： A method for enhancing the transfection efficiency of naked plasmid DNA in treating and/or preventing angiogenesis-dependent symptoms is provided by the present inventions. According to the present method, a suitable naked plasmid DNA is subjected for intramuscular injection under increased pressure inside the muscle or hyperbaric oxygen. Angiogenesis-dependent symptoms, including wounds, inflammatory diseases, critical limb ischemia, ischemia heart diseases, cerebral infarction, diabetic neuropathy, spinal canal stenosis, etc., may be treated by the present methods.
摘要翻译： 本发明提供了一种提高裸小质粒DNA在治疗和/或预防血管生成依赖性症状中的转染效率的方法。 根据本方法，将合适的裸质粒DNA在肌肉或高压氧内加压肌内注射。 可以通过本发明的方法治疗血管发生依赖性症状，包括伤口，炎性疾病，临界肢体缺血，缺血性心脏病，脑梗塞，糖尿病性神经病变，椎管狭窄等。
-
公开(公告)号：US20060135452A1
公开(公告)日：2006-06-22
申请号：US10536274
申请日：2003-12-02
IPC分类号： A61K48/00
CPC分类号： C07K14/475 , A61K48/0016 , A61K48/0083 , C07K14/4753 , C12N9/0073
摘要： A method for enhancing the transfection efficiency of naked plasmid DNA in treating and/or preventing angiogenesis-dependent symptoms is provided by the present inventions. According to the present method, a suitable naked plasmid DNA is subjected for intramuscular injection under increased pressure inside the muscle or hyperbaric oxygen. Angiogenesis-dependent symptoms, including wounds, inflammatory diseases, critical limb ischemia, ischemic heart diseases, cerebral infarction, diabetic neuropathy, spinal canal stenosis, etc., may be treated by the present methods.
摘要翻译： 本发明提供了一种提高裸小质粒DNA在治疗和/或预防血管生成依赖性症状中的转染效率的方法。 根据本方法，将合适的裸质粒DNA在肌肉或高压氧内加压肌内注射。 可以通过本发明的方法治疗血管发生依赖性症状，包括伤口，炎性疾病，临界肢体缺血，缺血性心脏病，脑梗塞，糖尿病性神经病变，椎管狭窄等。
-
10.发明申请Decoy compositions for treating and preventing brain diseases and disorders 审中-公开用于治疗和预防脑部疾病和疾病的诱饵组合物公开(公告)号：US20060135449A1
公开(公告)日：2006-06-22
申请号：US10509799
申请日：2002-03-29
CPC分类号： A61K9/0019 , A61K9/127 , A61K31/711 , A61K48/005 , A61K48/0075 , C07K14/4705 , C12N15/1131 , C12N15/115 , C12N15/86 , C12N2310/13 , C12N2310/315 , C12N2760/18811
摘要： The present invention provides introduction of NF-κB decoy oligodeoxynucleotide into rat cranial nerve through a carotid artery during global brain ischemia. Polymerase chain reaction demonstrated that one hour after global brain ischemia, transfected NF-κB decoy oligodeoxynucleotide effectively suppressed expression of tumor necrosis factor α, interleukin 1β and intracellular adhesion molecule 1 messenger RNAs. Terminal deoxynucleotidyl transferase-mediated deoxyuridine nick-end labeling staining and immunohistochemistry using microtubule-associated protein 2 demonstrated that transfected NF-κB decoy oligodeoxynucleotide significantly attenuated neuronal damage seven days after global brain ischemia. Therapeutic transfection of NF-κB decoy oligodeoxynucleotide during brain ischemia may be effective for attenuation of neuronal damage, suggesting a strategy for protecting the cerebrum from global ischemia.
摘要翻译： 本发明提供了在全脑缺血期间通过颈动脉将NF-κB诱饵寡脱氧核苷酸引入大鼠颅神经中。 聚合酶链反应表明，全球脑缺血后1小时，转染的NF-κB诱饵寡脱氧核苷酸有效抑制肿瘤坏死因子α，白细胞介素1β和细胞内粘附分子1信使RNA的表达。 末端脱氧核苷酸转移酶介导的脱氧尿苷切口标记染色和使用微管相关蛋白2的免疫组织化学证实，转染的NF-κB诱饵寡脱氧核苷酸在全脑缺血后7天显着减弱神经元损伤。 在脑缺血期间，NF-κB诱饵寡脱氧核苷酸的治疗转染对于减少神经元损伤可能是有效的，这表明保护大脑免受全身缺血的策略。
-
-
-
-
-
-
-
-
-
搜索结果
68 条记录 (耗时 0.026 秒)
